Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • AstraZeneca...

    AstraZeneca Prescription Savings Programs brought savings worth 617m dollars

    Written by savita thakur thakur Published On 2016-03-05T11:42:49+05:30  |  Updated On 5 March 2016 11:42 AM IST
    WILMINGTON: AstraZeneca announced that its AZ&Me™ Prescription Savings Programs provided more than $617 million in savings on medicines to patients in the United States in 2015. The programs supported nearly 322,500 patients last year.

    “As the healthcare market continues to change, patients sometimes need support in paying for their prescription medicines,” said Diane Sullivan, Vice President, Market Access and Patient Strategies. “We are proud of our long-standing commitment to making great medicines – and helping patients access them.”

    Since 2010, AstraZeneca has provided more than $5.5 billion in savings to patients in its savings programs. The programs are designed to help qualifying people without insurance, those enrolled in Medicare Part D, those who receive their medications through participating healthcare facilities and those who recently faced a financial challenge – such as loss of a job.

    • Individuals without Prescription Drug Coverage: AstraZeneca provides free medicines to qualifying individuals with an annual income at or below $35,000 and families of four with an annual household income at or below $70,000. Certain specialty and oncology medicines are provided free to qualifying individuals with an annual household income up to $100,000 regardless of family size.

    • Part D Beneficiaries: AstraZeneca provides free medicines to qualifying Medicare Part D beneficiaries with an annual income at or below $35,000 and couples with an annual household income at or below $48,000.

    • Healthcare Facilities: AstraZeneca provides free medicines to qualifying non-profit organizations, such as disproportionate share hospitals, community health centers and community free clinics. This program helps provide medicines to qualifying patients at the time and place of treatment.


    AstraZeneca first launched its prescription savings program more than 35 years ago, helping millions of patients afford the medicines they need. The company also participates in multi-manufacturer programs like the Partnership for Prescription Assistance and support other organizations with the same goal—increasing access to medicines as well as healthcare.
    AstraZenecaAZ&Me™ Prescription Savings ProgramsDiane SullivanMedicare Part Doncology
    Source : Press release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok